AcelRx commences third ARX-01 Phase 3 research in post-operative pain AcelRx Pharmaceuticals.

, a specialty pharmaceutical organization focused on the advancement and commercialization of innovative therapies for the treatment of acute and breakthrough discomfort, today announced dosing of the 1st patient in the third of three planned Phase 3 research for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system. ‘The beginning of our third Stage 3 clinical trial for ARX-01 is an essential milestone for our business lead Sufentanil NanoTab development system,’ said Richard King, AcelRx’s president and CEO.’ This third study is designed to enroll approximately 400 patients, randomized 3:1 to get 15 mcg Sufentanil NanoTabs or placebo NanoTabs.S..Another reason can be disappointments in muscle mass accumulation efforts despite spending a fortune in bogus supplements and anabolic steroids. If getting boozed isn’t bringing outcomes many an addict body builders who previously relied on steroids and supplements may quickly resolve to reform. Another justification is influence. If another body builder does it natural and getting results for it, a body builder who is having a hard time with the substances gets motivated to go organic too.